Author Manuscript Published OnlineFirst on April 30, 2014; DOI: 10.1158/1535-7163.MCT-13-1000 3 Introduction MicroRNAs (miRs) are a group of endogenous non-coding RNAs that post-transcriptionally regulate expression of protein-coding genes by recognizing specific mRNAs with complementary sequence (1, 2). miRs imperfectly match the 3'UTR of target mRNAs and inhibit translation and/or promote degradation. miR's can also target regions other than 3'UTR to trigger degradation of target mRNAs or repress protein synthesis. miRs are estimated to represent about 1% of all genes in human genome and the importance of their biological functions are being intensively investigated (3-5). miRs are associated with cancer as either oncogenes or tumorsuppressor genes and in cancer cells they are either up or down regulated (6-8). Many miRs up regulated in colon adenomas or adenocarcinomas have been reported (6). Recent reports have shown that miR-26b is under expressed in human breast cancer, parathyroid tumor, oral lichen planus disease, glioma cells, hepatocellular carcinomas, nasopharyngeal carcinomas, primary squamous cell lung carcinomas and squamous cell carcinoma of the tongue (9-16). Recently, two new target genes of miR-26b have been reported in glioma cells (EphA2) and human breast cancer cells (SLC7A11) (9, 12). EphA2 is an erythropoietin-producing hepatocellular (EPH)
Introduction
MicroRNAs (miRs) are a group of endogenous non-coding RNAs that post-transcriptionally regulate expression of protein-coding genes by recognizing specific mRNAs with complementary sequence (1, 2) . miRs imperfectly match the 3'UTR of target mRNAs and inhibit translation and/or promote degradation. miR's can also target regions other than 3'UTR to trigger degradation of target mRNAs or repress protein synthesis. miRs are estimated to represent about 1% of all genes in human genome and the importance of their biological functions are being intensively investigated (3) (4) (5) . miRs are associated with cancer as either oncogenes or tumorsuppressor genes and in cancer cells they are either up or down regulated (6) (7) (8) . Many miRs up regulated in colon adenomas or adenocarcinomas have been reported (6) . Recent reports have shown that miR-26b is under expressed in human breast cancer, parathyroid tumor, oral lichen planus disease, glioma cells, hepatocellular carcinomas, nasopharyngeal carcinomas, primary squamous cell lung carcinomas and squamous cell carcinoma of the tongue (9) (10) (11) (12) (13) (14) (15) (16) . Recently, two new target genes of miR-26b have been reported in glioma cells (EphA2) and human breast cancer cells (SLC7A11) (9, 12) . EphA2 is an erythropoietin-producing hepatocellular (EPH)
A receptor and activation of this receptor tyrosine kinase is associated with cancer cell growth (12) . SLC7A11 is a solute carrier family seven member eleven that may play a role in providing resistance to apoptosis in cells (9) . Lastly, human embryonic stem cells and metastatic colorectal cancer cells also express miR-26b, which may regulate TAF12, PTP4A1, CHFR and ALS2CR2 gene expression (17) .
Wnt signaling is one of the most important and best characterized signaling pathways involved in embryonic development, cell proliferation and cancer progression. The canonical Wnt signaling pathway is activated when Wnt ligand binds to cell surface receptor Frizzled and LRP, which activate Dishevelled and releases β-catenin from its destroying complex formed by Axin, APC and GSK3β. The released β-catenin enters nucleus and binds to Lef/Tcf transcription factors to activate downstream gene expression (18) . Among those components, many of them are potential targets of miR regulation.
In the case of colorectal cancer, mutation of Wnt signal components are estimated to cause approximately 90% of the cancer (19) (19) phosphorylation sites in β-catenin involved in its degradation. Targeting the Wnt/β-catenin pathway, especially the downstream transcriptional regulation, would be effective in therapeutic treatment. We previously demonstrated that miR-26b was a potent inhibitor of LEF-1 expression (20) . Given the critical role of LEF-1 in canonical Wnt signaling, colon cancer progression (21) and human sebaceous tumors (22) , we asked if miR-26b repression of LEF-1 would inhibit colon cancer cell proliferation.
Materials and Methods

Expression and reporter constructs
hsa-miR-26b precursor (addition of six thymine deoxyriboside at 3') was cloned from the genomic DNA of HEK 293 cell and was linked to U6 promoter in pLL3.7 backbone. Human LEF-1 cDNA was cloned from total mRNA of HEK 293 cell and was inserted downstream of EF1α promoter in pWPI backbone. The 7xTopFlash reporter plasmid was constructed into luciferase vector by inserting seven LEF/TCF binding sites upstream of the minimal TK promoter (20) . The 7xFopFlash negative control contains mutations within each LEF/TCF binding site. All constructs were confirmed by DNA sequencing.
Lentiviral vector generation and cell proliferation assays
A second generation Lentiviral vector system was used. The packaging vectors are psPAX2 and pMDG.
The gene expression vectors were transfected with packaging vectors into HEK 293 FT cells to generate lentiviral vectors as previously described (23) . The virus containing cell medium was harvested 48 hours after transfection. The viral vectors were concentrated by ultracentrifuge at 26,000 rpm for 2 hours at 4 0 C and added to the SW480 cell medium with 8 µg/ml polybrene. Infected cells were subject to the cell proliferation assay. Cells (150,000) were seeded in 60 mm plates on day 0 and then trypsinized and counted after 24, 48, 72 and 96 hours by a Coulter Z1 cell counter as previously described (24) . Experiments were run in triplicate. CCD 841 CoN, SW480, DLD-1, Colo 320 and HEK 293 cells were obtained from ATCC (cultured and frozen immediately for storage and used within 3 months; cell cultures used in revision experiments were subsequently thawed and cultured and genotypes were confirmed to previous cell cultures) and cultured in DMEM supplemented with 10% FBS and penicillin/streptomycin. SW480 cells were seeded in 12 well plates and transfected by Fugene HD (Roche) with 500 ng of reporter plasmid, 500 ng of expression plasmid and 50 ng SV-40 driven β-galactosidase plasmid. Transfected cells were incubated for 48 hours and then lysed for reporter activities and protein content by Bradford assay (Bio-Rad) as previously described (25) . Luciferase activity was measured with reagents from Promega and β-galactosidase activity was assessed by Galacto-Light Plus reagents (Tropix). Experiments were run in triplicate and all luciferase activities were normalized to β-galactosidase activity.
Real-time PCR analyses
Cells were cultured in T-75 flasks and 2 flasks of 80% confluent cells were harvested by scraping and miR isolation. Total RNA including miR from cells was prepared using the miRNeasy Mini Kit (Qiagen).
Mulitple isolations were performed and separate qPCR assays were run on each sample (N=3). The amount and integrity of the RNA samples were assessed by measurement at 260 and 280 nm and gel analyses. performed to confirm amplification specificity of the PCR products. PCR primers are LEF-1 F 5'-TTCCTTGGTGAACGAGTCTG-3', R 5'-CTCTGGCCTTGTCGTGGTAG-3'; cyclin D1 F 5'-ACACGCGCAGACCTTCGTTG-3', R 5'-GTAGGACAGGAAGTTGTTGG-3'; c-MYC F 5'-GATTCTCTGCTCTCCTCGAC-3', R 5'-GTGATCCAGACTCTGACCTT-3'. β-actin primers were described previously (26) .
Western blot assays
Endogenous LEF-1 isoforms were identified in colon cells and HEK 293 cells using the LEF-1 antibody Tunel Assay SW480 cells stably expressing scramble shRNA or miR-26b were grown to 75% confluence on glass slides and incubated for 2 hours with or without 0.5 mM H 2 O 2. The TUNEL assay was performed with the DeadEnd™ Fluorometric TUNEL System (Promega) according to the manufacturer's instruction.
Statistics
Statistics of growth curves were performed by the repeated measures analysis of variance (ANOVA).
Other statistics were performed by two-sample t-test. p-values less than 0.05 were considered to be significant.
Results
miR-26b expression is inversely correlated with LEF-1 expression in several colon cancer cell lines.
The non-tumor colon epithelial cell line (CCD 841 CoN, from ATCC) was set as a control to compare the relative expression of LEF-1 and miR-26b in non-cancer colon vs. colon cancer cells. miR-26b was significantly down regulated in colon cancer cell lines compared to the normal cells. miR-26b expression in normal cells was approximately 7.4, 12.3 and 37 times higher than observed in DLD-1, SW480, Colo 320 colon cancer cells, respectively (Fig. 1A) . In contrast, LEF-1 isoform expression was up regulated in the cancer cells at both the mRNA level and protein level (Fig. 1B, C) . A gradient of LEF-1 expression was detected where normal cells <DLD-1 <SW480 <Colo 320 (Fig. 1B, C) and the data indicated an inverse relationship between miR-26b and LEF-1 isoform expression in these cell lines. c-Myc, a LEF-1 target gene was also correlated with increased LEF-1 expression (Fig. 1B) . This inverse correlation suggests an inhibitory role of miR-26b on LEF-1 expression and indicated that miR-26b may have a potent regulatory role during cancer progression. miR-26b targets all LEF-1 isoforms as they contain identical 3'UTRs and miR-26b binding sites. Furthermore, we analyzed miR-26b expression in 54 human colon cancer specimens compared to 20 normal colon specimens from the NCBI's Gene Expression Omnibus public database (GSE30454) (27) . These data show decreased miR-26b expression (p<0.005) in human colon cancer tissue (Fig. 1D) . Because SW480 cells exhibited moderate expression of both LEF-1 and miR-26b we used these cells for over expression and knockdown treatments of both genes in cell proliferation assays.
miR-26b represses colon cancer cell proliferation.
To test whether miR-26b effected colon cancer proliferation, we established a variety of overexpression, knockdown and rescue cell lines and analyzed their proliferation (Fig. 2) . Human miR-26b and control scramble shRNA were inserted downstream of the U6 promoter in pLL3.7 plasmid. Human LEF-1 FL mRNA (full length isoform) was inserted downstream of the EF1α promoter in pWPI plasmid (Fig. 2A) (Fig.   3A) . Western blots showed that LEF-1 protein and mRNA levels were similar in these cell lines (Fig. 3B) . A Topflash reporter assay was used to examine the overall Wnt/β-catenin signal activity. SW480 cells were transfected with 7xTopflash reporter plasmid and indicated expression plasmids, together with SV-40 β-galactosidase as a control. Transfection with miR-26b decreased Topflash activity compared with control cells, while anti-miR-26b and LEF-1 transfection increased reporter activity. The Fopflash plasmid with a mutation in each LEF/TCF binding site was used as a negative control (Fig. 3C) . These data indicated that miR-26b had a potent inhibitory effect on LEF-1 expression as well as Wnt/β-catenin signal activity in colon cancer cells.
miR-26b represses expression of the LEF-1 target genes cyclin D1 and c-MYC.
Wnt/β-catenin signaling regulates cell proliferation through several different mechanisms (18, 19) . One of the most important mechanisms is through regulation of Cyclin D1 and c-Myc, which are essential regulators of cell proliferation and direct targets of the LEF-1/β-catenin transcription complex (28) (29) (30) . Therefore, we wanted to determine whether expression of these two genes was altered in our lentiviral-infected cells, which exhibit different rates of cell proliferation (Fig. 2C) . Real-time PCR showed that Cyclin D1 and c-Myc mRNA levels were decreased in miR-26b overexpressing cells compared to control cells, while they were increased in anti-miR-26b transfected and LEF-1 FL overexpressing cells (Fig. 4A, B) . Western blots showed that there were parallel changes in c-Myc and Cyclin D1 protein and mRNA levels (Fig. 4C) , suggesting that miR-26b repressed c-Myc and Cyclin D1 expression through inhibition of LEF-1 in colon cancer cells. As a control miR26b expressing cells were transfected with the LEF-1 FL cDNA, which is not targeted by miR-26b to demonstrate Lef-1 FL expression by the Western blot (Fig. 4C) . To test the effect of miR-26b inhibition on growth of colon cancer cells in vivo, we injected male nude mice (Foxn1 nu , aged 6-7weeks) with SW480 cells (1×10 (Fig. 5A) . After 33 days, mice were sacrificed and the tumors were collected for weighing and expression of miR-26b and other related genes. The average weight of miR-26b tumors were about 50% of the control tumors (Fig. 5B, C) and real-time PCR analyses showed that miR-26b expression was significantly increased in miR-26b tumors, while LEF-1, c-Myc and Cyclin D1 were significantly decreased in tumors derived from miR-26b overexpressing SW480 cells (Fig.   5D , E). These data were consistent with the in vitro cell proliferation assay and real-time PCR results.
miR-26b inhibits tumor growth in a xenograft
Tumor growth inhibition due to decreased proliferation not apoptosis.
To test whether miR-26b inhibited colon cancer cells through apoptosis, we performed TUNEL assays. SW480 cells stably expressing scramble miR (control) or miR-26b were stained with Promega TUNEL assay kit and almost no apoptosis was detected in either control or miR-26b cell lines (Fig. 6A,B) . The same cell lines were treated with 0.5 mM H 2 O 2 for 2 hours as positive controls. After H 2 O 2 treatment, apoptosis was induced in both cell lines (Fig. 6A,B) . These data suggest that miR-26b expression does not affect apoptosis of colon cancer cells in the presence or absence of oxidative stress indicating that miR-26b primarily regulates colon cancer cell/tumor proliferation and not survival.
Discussion
The role of LEF-1 in colon cancer.
We previously demonstrated that miR-26b not only targets the β-catenin responsive isoform of LEF-1 FL but also the dominant negative isoform (LEF-1ΔN) and intermediate isoform because they share the same 3'UTR. Thus, miR-26b also reduces expression of the dominant negative isoform. However, many colon cancer responsive to Wnt/β-catenin signaling in colon cancer cells (19) . LEF-1 and TCF belong to a family of DNA binding transcription factors that interact with β-catenin to activate genes involved in cell proliferation, morphogenesis, epithelial-mesenchymal transition and stemness, which can lead to cancer progression (32) (33) (34) (35) (36) .
The LEF-1 full-length and intermediate isoforms are produced in colon cancers through Wnt signaling and the LEF-1ΔN isoform is produced by an alternative promoter, which is inactive in some cancers (31, 37) .
Furthermore, β-catenin also activates Cyclin D1 expression in colon carcinoma cells through TCF/LEF-1 binding elements in the Cyclin D1 promoter (29, 30) . The c-Myc promoter contains multiple Tcf-4 binding sites and is activated by β-catenin and presumably by LEF-1 (28) . These data demonstrate the role for LEF-1/TCF and β-catenin in activating Cyclin D1 and c-Myc expression in cancer cells and our studies demonstrate that miR-26b targets LEF-1 expression, which in turn regulates Cyclin D1 and c-Myc expression.
c-Myc regulation of miRs and cancer.
Myc is a well-known oncogenic transcription factor that controls many cellular processes including cell growth, differentiation, cell adhesion and motility. Aberrant Myc activity is associated with many human cancers and Myc-mediated transactivation of target genes results in deregulated gene expression. Interestingly, some of these Myc target genes are miRs. Myc directly activates transcription of the polycistronic miR-17-92 cluster and miR-9 (38) (39) (40) . The miR-17-92 cluster is classified as an oncogene as its expression is associated with several solid tumors (for reviews see (41, 42) ). Conversely, Myc represses several miRNAs that are tumor suppressors including let-7 family members, miR-34a, miR-29 members, miR-26a and miR-15a/16-1 (43).
Myc-regulated miRs control cell cycle programs, apoptosis, angiogenesis, metabolism and therefore tumorigenesis through a variety of molecular mechanisms and gene targets (41, 42) . miR-26a over expression has been used in a MYC-driven mouse hepatocellular carcinoma model to reverse disease progression (44) . The molecular mechanism of miR-26a involved decreased expression of Cyclin D1 and D2 and induced cell cycle arrest (44) . Our data suggests that miR-26b overexpression could potentially be used in patients as a therapeutic, targeting hepatocellular carcinoma in these patients or a combination of miR-26a and b. Similar to miR-26a, (Fig. 1A) (17) . Interestingly, there is a direct correlation to the severity of colon cancer with a decrease miR-26b expression and a concomitant increase in LEF-1 expression suggesting that miR-26b could be an effective therapeutic agent in treating this disease. miR-26b was also decreased in LoVo colon cancer cells and miR-26b over expression in these cells suppressed cell growth and tumor growth in vivo (17) .
However, LEF-1 was not included as a miR-26b target in the LoVo cells and tumors.
In summary, miR-26b is decreased and LEF-1 expression is increased in colon cancer cells. We show an inverse correlation between miR-26b and LEF-1 expression in multiple colon cell lines (Fig. 1A and 1B) and that miR-26b has a potent inhibitory effect on colon cancer cell proliferation (Fig. 2) . Furthermore, in patient colon cancer samples miR-26b expression is decreased (Fig. 1D) . Endogenous LEF-1 expression is significantly decreased by miR-26b over expression and the Wnt/β-catenin target genes Cyclin D1 and c-Myc are also repressed, and this represents the underlying mechanism of miR-26b-dependent inhibition of colon cancer cell proliferation. Thus, miR-26b is a tumor repressor that is a potent inhibitor of colon cancer cell proliferation that blocks Wnt/β-catenin dependent activation of LEF-1 and a model for tumor suppressor-like activity of miR-26b is illustrated in figure 6C . These findings also have important therapeutic implications.
Given the prevalence of increased Wnt/β-catenin signaling in colon cancer patients, miR-26b can be a potential candidate for gene therapy of multiple cancer types that express LEF-1. The efficient delivery of miRs and other nucleic acids are being extensively investigated with some clinical trials already in progress (4, 5) . Fig. 1. Endogenous LEF-1 and miR-26b expression among colon cancer cell lines. A, B 
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